This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Integra Closes Codman Buyout, Strengthens Neurosurgery Arm
by Zacks Equity Research
With Codman's acquisition by Integra (IART), the neurosurgery business is likely to drive the company's 2018 adjusted earnings per share with a minimum yield of 22 cents.
Will Gilead & AbbVie Benefit from Merck's Decision to Drop Two HCV Programs?
by Arpita Dutt
With Merck (MRK) discontinuing the development of two HCV candidates, here's a look at what to expect from the remaining key players in the HCV market.
The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO
Abbott Gets FDA Nod for FreeStyle Libre, Boosts Diabetes Arm
by Zacks Equity Research
Abbott's (ABT) diabetes care segment to strengthen with the FDA approval for FreeStyle Libre Flash glucose monitoring system.
3 Biotech and Pharma Stocks with Key FDA Catalysts this October
by Arpita Dutt
Here is a look at three biotech and pharma stocks including Flexion (FLXN) that have an important regulatory event lined up this month.
Merck Drops Two HCV Combination Programs Amid Competition
by Zacks Equity Research
Merck (MRK) is discontinuing the development of two of its hepatitis C (HCV) programs - MK-3682B and MK-3682C - as the HCV market is becoming extremely crowded.
Quality Dividend ETFs for Turbulent Times
by Zacks Equity Research
Consider these 3 dividend ETFs for your portfolio to fight rising market uncertainty.
How Will Trump's Proposed Tax Reform Impact Drug Companies?
by Zacks Equity Research
Donald Trump has proposed new tax reforms for individuals and corporates. Let's see how the reforms, if passed, will impact pharma companies.
The Zacks Analyst Blog Highlights: Goldman Sachs Group, PepsiCo, Johnson & Johnson, Cummins and Fidelity National Information Services
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Goldman Sachs Group, PepsiCo, Johnson & Johnson, Cummins and Fidelity National Information Services
Impax Generic Division Progresses Well Amid Pricing Pressure
by Zacks Equity Research
Impax Laboratories' (IPXL) generic portfolio has progressed well so far this year. Moreover, approval of the generic versions of Vytorin and Concerta is a positive.
Top Stock Reports for Goldman Sachs, PepsiCo and Johnson & Johnson
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Goldman Sachs Group Inc (GS), PepsiCo, Inc. (PEP) and Johnson & Johnson (JNJ)
J&J's Arthritis Candidate Sirukumab Denied FDA Approval
by Zacks Equity Research
J&J (JNJ) said that the FDA has denied approval to its investigational rheumatoid arthritis treatment, sirukumab for want of additional safety data.
Allergan's (AGN) Vraylar Gets RTF From FDA, New Data for CVC
by Zacks Equity Research
The FDA slaps a refusal-to-file letter on Allergan's (AGN) Vraylar for its supplemental New Drug Application. The company tries to expand the drug???s label for its use as a maintenance treatment.
Here's Why These 3 Biotech Stocks Might Stop Rallying (Revised)
by Zacks Equity Research
The momentum in the biotech sector is likely to continue. However, it's a good idea to avoid a few stocks that will possibly lose their momentum soon despite significant gains year to date.
Karyopharm's Liposarcoma Candidate Superior in Phase II Study
by Zacks Equity Research
Karyopharm's (KPTI) selinexor reduced the risk of progression or death in previously treated patients with advanced dedifferentiated liposarcoma.
Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake
by Zacks Equity Research
Pfizer (PFE) filed a lawsuit in a U.S. district court alleging that J&J is resorting to anticompetitive practices to prevent uptake of Inflectra.
Here's Why These 3 Biotech Stocks Might Stop Rallying
by Zacks Equity Research
The momentum in the biotech sector is likely to continue. However, it's a good idea to avoid a few stocks that will possibly lose their momentum soon despite significant gains year to date.
Top Research Reports for Northrop Grumman, BNY Mellon & Celgene
by Zacks Equity Research
Today's Research Daily features new research reports on 16 major stocks, including Northrop Grumman (NOC), Bank of New York Mellon (BK) and Celgene (CELG)
Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia
by Zacks Equity Research
Alkermes (ALKS) announced encouraging results from a phase IV study of ARISTADA for the treatment of schizophrenia.
Catalyst (CPRX) Focused on Two Lead Pipeline Candidates
by Zacks Equity Research
: Catalyst (CPRX) remains focused on development of its two lead pipeline candidates, Firdapse and CPP-115.
J&J's (JNJ) Psoriasis Drug Guselkumab Gets CHMP Nod in EU
by Zacks Equity Research
J&J's (JNJ) pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis received a positive opinion from the CHMP in the EU.
Neos Therapeutics ADHD Drug Adzenys Receives Approval in US
by Zacks Equity Research
Neos Therapeutics (NEOS) announced the approval of its third ADHD drug Adzenys for the treatment of six years and older patients.
S&P 500 Makes History, Steers Past 2500: Top 5 Gainers
by Tirthankar Chakraborty
The S&P 500, America's dominant stock market index, is in a 'breakout mode' right now as it powered past 2,500 for the first time
Pfizer Xtandi Succeeds in Early Stage Prostate Cancer Study
by Zacks Equity Research
Pfizer's (PFE) prostate cancer drug Xtandi met the primary endpoint in a late-stage study, which can expand the label of the drug to include early-stage patients.
Amgen/Allergan's Avastin Biosimilar Secures FDA Approval
by Zacks Equity Research
The FDA approves Amgen-Allergan's biosimilar version of Roche's Avastin for treating multiple types of cancers, to be marketed by the trade name of Mvasi.